ReviewHeart rhythm O22025
The left atrium in heart failure with preserved ejection fraction: What we know and what we do not know.
Review in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine learning-based prediction of mortality and hospitalization in diabetic patients with heart failure with preserved ejection fraction: the GUARDIAN-P risk score.European heart journal. Digital health · 2026Article
- Prognostic value of left atrial diameter in chronic kidney disease: The KNOW-CKD study.Clinical medicine (London, England) · 2026Article
- Automated 4D flow MRI pipeline for the quantification of advanced hemodynamic parameters in the left atrium.Scientific reports · 2026Article
- Atrial FDG avidity is associated with reduced atrial strain and contractility independent of atrial fibrillation and cardiac sarcoidosis.European heart journal. Imaging methods and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous condition with a distinct pathophysiology involving both systemic and cardiac dysfunction. Its impact extends beyond the left ventricle, notably to the atrial chambers where atrial abnormalities manifesting with structural, functional, and electrophysiologic abnormalities demonstrate a bidirectional relationship with impaired ventricular filling. These atrial changes create a pro-arrhythmic substrate, fostering both initiation and perpetuation of atrial fibrillation. Conversely, atrial disease, including atrial fibrillation, exacerbates HFpEF by promoting further pathologic remodeling, aggravating diastolic dysfunction, and elevating filling pressures. This bidirectional interaction establishes a mutually reinforcing feedback loop, which is associated with increased morbidity and mortality. In this review, we will highlight key aspects of atrial cardiomyopathy associated with HFpEF and explore their impact on HFpEF pathophysiology and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.